Search

everythinglearnresearchcommunity

for

Search:↓

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

The conversation discusses hair loss treatment options, focusing on finasteride and its potential effects on gynecomastia. The user is considering finasteride while managing hormone levels with supplements like boron, vitamin D, zinc, magnesium, and P5P, and is advised to consult an endocrinologist for further evaluation.

A user shared their positive experience with Roots by GA, a company that creates personalized hair loss treatments based on DNA analysis, which confirmed their inability to tolerate finasteride. The user is satisfied with their progress 30 days after a hair transplant and the customized formula they received.

GHK-Cu and Acetyl Tetrapeptide-3 are ineffective for hair regrowth according to user experiences. Effective treatments mentioned are finasteride, dutasteride, and minoxidil.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.

Febron Hair fiber quality has decreased since post-pandemic era, causing fibers to stick to fingers. Users seek better brand recommendations.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

A 35-year-old transgender woman experienced hair regrowth with feminizing HRT, adding dutasteride and bicalutamide, and plans a hair transplant for further improvement. Estrogen also improved skin appearance, and the user advises against cisgender men using feminizing HRT for hair regrowth.

The conversation is about someone seeking information on long-term users of CB-03-01 for hair loss, having experienced negative side effects from finasteride and facing rapid hair thinning.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.

A 23-year-old male has been experiencing hair loss since 2022 and has used minoxidil and dutasteride with reduced shedding but no hair regrowth. He is considering PRP with mesotherapy and red light therapy, GFC, or exosomes, with a preference for exosomes due to efficiency and a reputable clinic.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

A user successfully managed finasteride-induced gyno symptoms by making lifestyle changes, including fasting, avoiding soy, and increasing cardio. They resumed finasteride with a lower dose combined with minoxidil and P7 vitamins without recurrence of symptoms.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

OP underwent a hair transplant (HT) and has been using finasteride for one year. Despite having thin hair, OP is happy with the results and feels more confident.

RU58841 was used by some for hair loss, but concerns about side effects like gynecomastia and safety were raised. Alternatives like finasteride, minoxidil, pyrilutamide, and alfatradiol were discussed, with some users reporting better experiences with these treatments.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.

A user shared their one-year hair regrowth progress using Minoxidil, Finasteride, T-gel, derma rolling, and biotin, expressing gratitude for the support received and commitment to continue the regimen. They are pleased with the results and plan to maintain their daily routine.

Theaflavin, a black tea extract, may inhibit DHT and androgen receptor activity, but its effectiveness for hair loss is debated. Users report no significant improvement with theaflavin, while some find beta sitosterol helpful.